UNSPSC 51343105: Emtricitabine

This classification denotes a reverse transcriptase inhibitor and pyrimidine antagonist with the molecular formula C8H10FN3O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G70B4ETF4S, chemically known as 5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine but generally known as emtricitabine, which bears US NIH Compound Identifier 60877. European Medicines Agency schedules Emtricitabine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01882MIG.

UNSPSC 51343105 Emtricitabine, a Commodity code, shows limited direct procurement activity under this specific pharmaceutical identifier in recent state and local solicitations. The code nominally covers emtricitabine, an antiretroviral medication used in HIV treatment regimens; however, the recent opportunities associated with it do not involve emtricitabine procurement itself. Instead, state and local bodies are buying a broader range of pharmaceutical products, medical supplies, and pharmacy program management services that may or may not include emtricitabine as a line item within larger multi-product frameworks. The Seminole County, Florida procurement (IFB 60459723LAS) focuses on naloxone and drug deactivation systems for community health support rather than antiretroviral therapy. The Texas Health and Human Services Commission RFI (HHS0017013) seeks vendor capability information for a direct-to-manufacturer prescription program without naming specific drugs. The City of Tampa's bid (26P00145) covers emergency medical and first aid supplies for the Fire Department. The Minnesota Multistate Cooperative Purchasing Alliance RFP (S1070000015802) establishes contracts for generic multi-source pharmaceuticals and OTC products through authorized wholesalers, a vehicle that could include emtricitabine but does not isolate it as a procurement focus.

The issuing bodies span county health departments, state health agencies, municipal fire departments, and cooperative purchasing alliances, indicating fragmented demand across health and emergency services. Geographic activity appears concentrated in Florida, Texas, and Minnesota based on recent postings. The MMCAP RFP represents a multi-state cooperative purchasing vehicle that includes Oregon alongside Minnesota participants, suggesting potential broader geographic reach through group purchasing arrangements. None of the recent opportunities explicitly prioritizes emtricitabine as a named product line or establishes standalone contracts for it. The code appears to sit within larger pharmaceutical procurement ecosystems where individual antiretroviral drugs are sourced through volume contracts, wholesaler networks, or multi-product frameworks rather than through direct, commodity-specific solicitations.